The present invention provides oligomeric compounds, in particular oligonucleotide compounds, and methods of treating a cancer using such oligomeric compounds. Particularly contemplated are oligomeric compounds which comprise a target binding domain that is specifically hybridisable to mRNA or genomic DNA encoding neonatal Nav1.5. In cancer cells that express nNav1.5, the oligomeric compound can reduce the level of nNav1.5 mRNA in cancer cells, the level of nNav1.5 in the cancer cells and/or the level of nNav1.5 expressed on the surface of the cancer cells. This is turn can reduce or prevent metastatic behaviour of the cancer, pain sensation in the patient, invasiveness of the cancer and/or overall aggressiveness of the cancer.
